Drug intelligence / Profile preview

HY6-F9WT

Development stage: Preclinical
Lead developer: University of Minnesota
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HY6-F9WT is a **wild-type monoclonal antibody (mAb) targeting fentanyl**, developed for the **treatment and prevention of fentanyl overdose and opioid use disorder**. This mAb binds selectively to fentanyl and fentanyl analogues, neutralizing their effects. In preclinical studies, HY6-F9WT demonstrated efficacy in reducing fentanyl-induced effects and lowering brain fentanyl levels in animal models. Its functional duration and pharmacokinetics have been compared with Fc-engineered variants designed for enhanced neonatal Fc receptor (FcRn) affinity and extended half-life. HY6-F9WT is the unmodified (wild-type) parental antibody in these studies[1][3][4][5].

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on HY6-F9WT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY6-F9WT.

Explore the full profile